NCT07617961 THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers
| NCT ID | NCT07617961 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Biointelligent Technology Systems SL |
| Condition | Chronic Wounds |
| Study Type | OBSERVATIONAL |
| Enrollment | 26 participants |
| Start Date | 2025-10-02 |
| Primary Completion | 2025-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 26 participants in total. It began in 2025-10-02 with a primary completion date of 2025-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions, pressure ulcers, diabetic ulcers, and chronic ulcers in 26 patients. The study evaluated wound healing progression, epithelialization, tissue hydration, inflammatory response, tolerance, and overall clinical evolution in patients receiving standard wound care combined with topical application of THERAVEX Tissue Care Spray Plus. Preliminary observations demonstrated favorable tissue response, progressive epithelial regeneration, reduction of inflammatory signs, and absence of treatment-related adverse events.
Eligibility Criteria
Inclusion Criteria Adult patients aged 18 years or older. Patients presenting with cutaneous wounds: burns, traumatic wounds, pressure ulcers, diabetic ulcers, or chronic cutaneous lesions. Patients considered clinically suitable for topical treatment with THERAVEX Tissue Care Spray Plus. Exclusion Criteria Known allergy or hypersensitivity to any component of THERAVEX Tissue Care Spray Plus. Presence of severe uncontrolled systemic infection requiring immediate surgical intervention. Participation in another interventional clinical study that could interfere with wound healing assessment.
Frequently Asked Questions
Who can join the NCT07617961 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Wounds. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07617961 currently recruiting?
Yes, NCT07617961 is actively recruiting participants. Visit ClinicalTrials.gov or contact Biointelligent Technology Systems SL to inquire about joining.
Where is the NCT07617961 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT07617961 clinical trial?
NCT07617961 is sponsored by Biointelligent Technology Systems SL. The trial plans to enroll 26 participants.